Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q7Z2K6

UPID:
ERMP1_HUMAN

ALTERNATIVE NAMES:
Felix-ina

ALTERNATIVE UPACC:
Q7Z2K6; B2RNA4; B3KSB1; Q8N5T5; Q9H5M1

BACKGROUND:
The protein Endoplasmic reticulum metallopeptidase 1, known alternatively as Felix-ina, is indispensable for ovarian function. It orchestrates the organization of somatic cells and oocytes into follicular structures, a process vital for reproductive success.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Endoplasmic reticulum metallopeptidase 1 offers a promising avenue for developing new therapeutic approaches. Given its critical role in ovarian follicle organization, targeting this protein could lead to breakthroughs in treating infertility and other reproductive disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.